Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
Business Wire•05/11/2026•17:29 ET
0
Key Highlights
- ➤$9.1 million cash; runway expected into second quarter of 2027
- ➤$3.3 million quarterly net loss versus $1.9 million year earlier
- ➤$9.6 million nine-month net loss versus $6.4 million year earlier
- ➤Gemini potential total addressable market estimated at $94 billion
- ➤Global CRO selected for upcoming Gemini acute kidney injury study
Expert Statements
James Rolke, Chief Executive Officer of Revelation Biosciences
“The Revelation team remains focused on progressing Gemini's development for the benefit of patients. We look forward to providing additional updates in the near term.”
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026.
Get started
Create a free account to read the full story.